Clear Rock Advisors LLC Buys 1,314 Shares of Zoetis Inc. (NYSE:ZTS)

Clear Rock Advisors LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 8.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,427 shares of the company’s stock after acquiring an additional 1,314 shares during the quarter. Zoetis makes up approximately 1.2% of Clear Rock Advisors LLC’s holdings, making the stock its 26th largest position. Clear Rock Advisors LLC’s holdings in Zoetis were worth $2,848,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Global Assets Advisory LLC purchased a new stake in shares of Zoetis in the 1st quarter worth about $8,831,000. Franklin Street Advisors Inc. NC increased its stake in shares of Zoetis by 4.3% in the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock worth $20,478,000 after acquiring an additional 5,035 shares in the last quarter. Prevail Innovative Wealth Advisors LLC lifted its position in Zoetis by 24.5% during the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after acquiring an additional 3,738 shares during the period. Finally, Logan Capital Management Inc. grew its holdings in Zoetis by 4.1% in the fourth quarter. Logan Capital Management Inc. now owns 117,480 shares of the company’s stock worth $23,187,000 after purchasing an additional 4,643 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.5 %

Shares of ZTS stock opened at $194.49 on Wednesday. The stock has a market capitalization of $88.74 billion, a P/E ratio of 37.47, a P/E/G ratio of 2.99 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm’s 50 day moving average is $186.64 and its 200 day moving average is $175.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter in the prior year, the company earned $1.41 earnings per share. Zoetis’s revenue was up 8.3% on a year-over-year basis. Research analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current year.

Analyst Ratings Changes

ZTS has been the topic of a number of analyst reports. BTIG Research upped their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.